By: Lecia Bushak
The lawsuit claims that Biogen denied patients “massive cost savings” by employing anticompetitive tactics to keep Tecfidera on formularies.
Lecia Bushak is a Senior Reporter at MM+M, focusing on health care news. With a background in journalism and production at local NPR and PBS stations, Lecia brings a unique perspective to her reporting. Her work has appeared in publications such as Campaign US and PRWeek, covering topics ranging from mental health influencers to pharmaceutical industry news.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Lecia Bushak's coverage primarily focuses on the healthcare and pharmaceutical industry, with a specific emphasis on health trends, medical research, and healthcare marketing. Her articles often contain press releases and cite data, indicating that she values factual information from reliable sources.
Given her focus on national coverage in the United States, Lecia would likely be receptive to pitches related to significant developments or trends in the US healthcare and pharmaceutical sectors. She may also be interested in insights from experts within these industries who can provide valuable commentary based on credible data.
Pitches should aim to provide unique perspectives or access to exclusive data that aligns with ongoing health trends or recent developments within the pharmaceutical industry for increased chances of engagement.
This information evolves through artificial intelligence and human feedback. Improve this profile .